Filing Flows › Pacific Biosciences of California (PACB) › Who owns the stock
Who owns Pacific Biosciences of California (PACB) stock
215 funds reported Pacific Biosciences of California (PACB) shares in their latest 13F filings, worth $364M in all. The largest holder is BlackRock ($54.3M). Last quarter 85 funds added to their stakes and 95 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| BlackRock | 32,339,550 | $54.3M | increase | 2026-06-30 |
| ARK Investment Management LLC | 29,781,416 | $50.0M | decrease | 2026-06-30 |
| Softbank Group | 20,451,570 | $34.4M | unchanged | 2026-06-30 |
| Vanguard Group | 17,037,314 | $31.9M | increase | 2025-12-31 |
| Vanguard Capital Management LLC | 13,397,934 | $22.5M | increase | 2026-06-30 |
| Geode Capital Management, LLC | 7,606,518 | $12.8M | increase | 2026-06-30 |
| Sumitomo Mitsui Trust Group | 6,009,715 | $10.1M | decrease | 2026-06-30 |
| Nikko Asset Management Americas | 6,009,715 | $10.0M | decrease | 2026-06-30 |
| State Street | 5,961,175 | $10.0M | decrease | 2026-06-30 |
| Point72 Asset Management, L.P. | 4,787,300 | $8.0M | increase | 2026-06-30 |
| Two Sigma Investments, LP | 4,242,599 | $7.1M | increase | 2026-06-30 |
| D. E. Shaw | 4,208,146 | $7.1M | increase | 2026-06-30 |
| Millennium Management LLC | 3,962,442 | $6.7M | decrease | 2026-06-30 |
| Point72 (DIFC) | 4,270,137 | $5.5M | increase | 2025-09-30 |
| Goldman Sachs Group | 3,229,887 | $5.4M | increase | 2026-06-30 |
Pacific Biosciences of California's latest quarter
Pacific Biosciences of California, Q3 2026: revenue $40.6M (+6% year over year), operating margin -91.2%, net loss $37.8M, operating cash flow −$37.6M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most PACB stock?
By the latest 13F filings: BlackRock ($54.3M); ARK Investment Management LLC ($50.0M); Softbank Group ($34.4M); Vanguard Group ($31.9M); Vanguard Capital Management LLC ($22.5M).
What is the short interest in PACB?
46,933,159 shares were sold short at the 2026-10-15 settlement, -0.62% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.